Biocompatibles wins IOM3 award for DC Bead technology


Polymer-based engineering solution deprives cancer cells of nutrients they need to survive

Left to right: Dr Peter Stratford, chief technical officer, Interventional Medicine at Biocompatibles UK receives the IOM3 award from HRH The Prince Philip

Biocompatibles UK, a medical technology company involved in drug device combination products, has won an award for the development of an innovative cancer product.

The Farnham, Surrey based firm received the Institute of Materials, Minerals and Mining (IOM3) award for Polymers in the Service of Mankind for its DC Bead technology from HRH The Prince Philip, in a ceremony at Buckingham Palace.

DC Bead is a polymer-based engineering solution that ultimately deprives cancer of the nutrients and oxygen that enable it to spread. It is used in a procedure called Transarterial Chemoembolisation (TACE), a minimally invasive medical procedure to restrict a tumour's blood supply. TACE has been used extensively to delay the progression of hepatocellular carcinoma (HCC), a type of liver cancer.

Biocompatibles UK’s main aim is to deliver products that are safe to use, economically viable, with clear clinical advantages. The firm's products use specialised polymer technology engineered to allow ease of delivery to blood vessels of tumours combined with controlled drug delivery capability. It is a pioneer in the use of drug-eluting beads to treat cancer.

Biocompatibles UK Ltd has been part of BTG International group company since 2008.

The Prince Philip award was established in 1973 and is awarded biennually (subject to sufficient merit).

Email this story